uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Svanberg, Anncarin
Publications (10 of 15) Show all publications
Walladbegi, J., Gellerstedt, M., Svanberg, A. & Jontell, M. (2018). Correction to: Innovative intraoral cooling device better tolerated and equally effective as ice cooling. Cancer Chemotherapy and Pharmacology, 81(1), 225-225
Open this publication in new window or tab >>Correction to: Innovative intraoral cooling device better tolerated and equally effective as ice cooling
2018 (English)In: Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, E-ISSN 1432-0843, Vol. 81, no 1, p. 225-225Article in journal (Refereed) Published
Abstract [en]

Unfortunately, the online published article has error in Table 1. The correct Table 1 is given in the following page.

National Category
Cancer and Oncology Pharmacology and Toxicology Pharmaceutical Sciences
Identifiers
urn:nbn:se:uu:diva-347111 (URN)10.1007/s00280-017-3465-8 (DOI)000419437500024 ()29086062 (PubMedID)
Note

The original article can be found online at https://doi.org/10.1007/s00280-017-3434-2

Available from: 2018-03-26 Created: 2018-03-26 Last updated: 2018-03-26Bibliographically approved
Hjorth, M., Sjöberg, D., Svanberg, A., Kaminsky, E., Langenskiöld, S. & Rorsman, F. (2018). Nurse-led clinic for patients with liver cirrhosis-effects on health-related quality of life: study protocol of a pragmatic multicentre randomised controlled trial.. BMJ Open, 8(10), Article ID e023064.
Open this publication in new window or tab >>Nurse-led clinic for patients with liver cirrhosis-effects on health-related quality of life: study protocol of a pragmatic multicentre randomised controlled trial.
Show others...
2018 (English)In: BMJ Open, ISSN 2044-6055, E-ISSN 2044-6055, Vol. 8, no 10, article id e023064Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: Liver cirrhosis affects health-related quality of life (HRQoL) even in its early stages. Morbidity is especially high when the disease decompensates and self-care actions become essential. Nurse involvement in secondary prevention in other chronic diseases has contributed to better symptom control, less need of inpatient care and improved HRQoL. In order to evaluate the impact of nurse involvement in the follow-up of patients with liver cirrhosis, we decided to compare structured nurse-led clinics, inspired by Dorothea Orem's nursing theory and motivational strategies, with a group of patients receiving standard care. The primary outcome is HRQoL and the secondary outcomes are quality of care, visits to outpatient clinics or hospitals, disease progress and health literacy.

METHODS AND ANALYSIS: This is a pragmatic, multicentre randomised controlled study conducted at six Swedish hepatology departments. Eligible patients are adults with diagnosed cirrhosis of the liver (n=500). Participants are randomised into either an intervention with nurse-led follow-up group or into a standard of care group. Recruitment started in November 2016 and is expected to proceed until 2020. Primary outcomes are physical and mental HRQoL measured by RAND-36 at enrolment, after 1 and 2 years.

ETHICS AND DISSEMINATION: The study is ethically approved by the Regional Ethical Review Board in Uppsala. The results shall be disseminated in international conferences and peer-reviewed articles.

TRIAL REGISTRATION NUMBER: NCT02957253; Pre-results.

Keywords
economics, health-related quality of life, liver cirrhosis, nurse-led clinic, nursing, qualituy of care
National Category
Nursing
Identifiers
urn:nbn:se:uu:diva-366222 (URN)10.1136/bmjopen-2018-023064 (DOI)000454739500129 ()30337316 (PubMedID)
Available from: 2018-11-18 Created: 2018-11-18 Last updated: 2019-01-25Bibliographically approved
Walladbegi, J., Svanberg, A. & Gellerstedt, M. (2018). Protocol for a randomised controlled trial to study cryoprevention of chemotherapy-induced oral mucositis after autologous stem cell transplantation. BMJ Open, 8(10), Article ID e021993.
Open this publication in new window or tab >>Protocol for a randomised controlled trial to study cryoprevention of chemotherapy-induced oral mucositis after autologous stem cell transplantation
2018 (English)In: BMJ Open, ISSN 2044-6055, E-ISSN 2044-6055, Vol. 8, no 10, article id e021993Article in journal (Refereed) Published
Abstract [en]

Introduction: A majority of patients who receive myeloablative therapy prior to hematopoetic stem cell transplantation develop oral mucositis (OM). This adverse cytotoxic effect manifests as oral mucosal erythema and ulcerations and frequently necessitates high doses of morphine for pain alleviation. OM may also interfere with food intake and result in parenteral nutrition, weight loss and impaired quality of life. To date, there have been a few studies of evidence-based interventions for prevention of OM. Cooling the oral mucosa using ice chips in conjunction with chemotherapy is known to reduce the severity of OM although clinical application is still limited due to several disadvantages. The primary endpoint of this study is therefore to evaluate the efficacy of an innovative intraoral cooling device (Cooral) compared with ice cooling in reducing the degree of OM, in patients with myeloma or lymphoma.

Method and analysis: A total of 180 patients from four different university hospitals in Sweden will be randomised to ice or Cooral in a proportion of 1:1. The degree of OM will be assessed at eight intraoral locations, in accordance with the Oral Mucositis Assessment Scale and WHO scale. Patients will be registered beginning at admission and will continue until discharge or until day +28. The primary variable is analysed in a multiple linear regression model. The significance level used is 5%.

Ethics and dissemination: The study protocol, questionnaire, diaries and letter of invitation to participants have been reviewed by the local ethical board in Goteborg. The trial results will be published in a peer-reviewed journal and disseminated to participants.

National Category
Hematology
Identifiers
urn:nbn:se:uu:diva-373979 (URN)10.1136/bmjopen-2018-021993 (DOI)000454739500069 ()30361399 (PubMedID)
Funder
VINNOVA
Available from: 2019-01-17 Created: 2019-01-17 Last updated: 2019-01-17Bibliographically approved
Walladbegi, J., Gellerstedt, M., Svanberg, A. & Jontell, M. (2017). Innovative intraoral cooling device better tolerated and equally effective as ice cooling. Cancer Chemotherapy and Pharmacology, 80(5), 965-972
Open this publication in new window or tab >>Innovative intraoral cooling device better tolerated and equally effective as ice cooling
2017 (English)In: Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, E-ISSN 1432-0843, Vol. 80, no 5, p. 965-972Article in journal (Refereed) Published
Abstract [en]

Most of the patients who receive myeloablative therapy prior to stem cell transplantation develop oral mucositis (OM). This adverse reaction manifests as oral mucosal erythema and ulcerations and may require high doses of morphine for pain alleviation. OM may also interfere with food intake and result in weight loss, a need for parenteral nutrition, and impaired quality of life. To date, there have been very few studies of evidence-based interventions for the prevention of OM. Cryotherapy, using ice chips, has been shown to reduce in an efficient manner the severity and extent of OM, although clinical applications are still limited due to several shortcomings, such as adverse tooth sensations, problems with infectious organisms in the water, nausea, and uneven cooling of the oral mucosa. The present proof-of-concept study was conducted to compare the tolerability, temperature reduction, and cooling distribution profiles of an intra-oral cooling device and ice chips in healthy volunteers who did not receive myeloablative treatment, and therefore, did not experience the symptoms of OM. Twenty healthy volunteers used the cooling device and ice chips for a maximum of 60 min each, using a cross-over design. The baseline and final temperatures were measured at eight intra-oral locations using an infra-red thermographic camera. The thermographic images were analysed using two digital software packages. A questionnaire was used to assess the tolerability levels of the two interventions. The intra-oral cooling device was significantly better tolerated than the ice-chips (p = 0.0118). The two interventions were equally effective regarding temperature reduction and cooling distribution. The intra-oral cooling device shows superior tolerability in healthy volunteers. Furthermore, this study shows that temperature reduction and cooling distribution are achieved equally well using either method.

Keywords
Cryotherapy, Tolerability, Healthy volunteers, Intra-oral cooling device, Oral mucositis, Myeloablative therapy
National Category
Cancer and Oncology Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-341946 (URN)10.1007/s00280-017-3434-2 (DOI)000414762300009 ()28975429 (PubMedID)
Available from: 2018-02-16 Created: 2018-02-16 Last updated: 2018-02-16Bibliographically approved
Walladbegi, J., Svanberg, A. & Jontell, M. (2017). Optimal cooling temperature to prevent adverse effects of chemotherapeutic agents. Paper presented at 43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), MAR 26-29, 2017, Marseille, FRANCE. Bone Marrow Transplantation, 52(Supplement: 1), S301-S302
Open this publication in new window or tab >>Optimal cooling temperature to prevent adverse effects of chemotherapeutic agents
2017 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 52, no Supplement: 1, p. S301-S302Article in journal, Meeting abstract (Other academic) Published
National Category
Hematology
Identifiers
urn:nbn:se:uu:diva-351612 (URN)10.1038/bmt.2017.134 (DOI)000424355301314 ()
Conference
43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), MAR 26-29, 2017, Marseille, FRANCE
Note

In: Abstracts From The 43RD Annual Meeting Of The Europeansociety For Blood And Marrow Transplantation:Physicians—Posters Session (P001-P738).

Meeting Abstract: P357

Available from: 2018-06-08 Created: 2018-06-08 Last updated: 2018-06-08Bibliographically approved
Kamsvåg-Magnusson, T., von Essen, L., Arvidson, J., Svanberg, A., Mellgren, K., Garming-Legert, K., . . . Ljungman, G. (2017). Oral Cryotherapy to Reduce the Incidence of Severe Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: Results of a Randomized Clinical Trial. Pediatric Blood & Cancer, 64(S3), S360-S361
Open this publication in new window or tab >>Oral Cryotherapy to Reduce the Incidence of Severe Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: Results of a Randomized Clinical Trial
Show others...
2017 (English)In: Pediatric Blood & Cancer, ISSN 1545-5009, E-ISSN 1545-5017, Vol. 64, no S3, p. S360-S361Article in journal, Meeting abstract (Other academic) Published
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-346781 (URN)000408978203227 ()
Available from: 2018-03-22 Created: 2018-03-22 Last updated: 2018-03-22Bibliographically approved
Legert, K. G., Svanberg, A., Zuckerman, T., Ram, R., Kolomansky, A., Romejko-Jarosinska, J. & Nasilowska-Adamska, B. (2016). Effect of episil (R) oral liquid on oral mucositis severity and duration in HSCT patients. Paper presented at 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, APR 03-06, 2016, Valencia, SPAIN. Bone Marrow Transplantation, 51, S410-S411
Open this publication in new window or tab >>Effect of episil (R) oral liquid on oral mucositis severity and duration in HSCT patients
Show others...
2016 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 51, p. S410-S411Article in journal, Meeting abstract (Other academic) Published
National Category
Cancer and Oncology Hematology
Identifiers
urn:nbn:se:uu:diva-299155 (URN)000373357601186 ()
Conference
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, APR 03-06, 2016, Valencia, SPAIN
Available from: 2016-07-15 Created: 2016-07-15 Last updated: 2017-11-28Bibliographically approved
Svanberg, A. & Birgegård, G. (2015). Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting. Oncology, 89(1), 31-36
Open this publication in new window or tab >>Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting
2015 (English)In: Oncology, ISSN 0030-2414, E-ISSN 1423-0232, Vol. 89, no 1, p. 31-36Article in journal (Refereed) Published
Abstract [en]

Chemotherapy-induced nausea/vomiting (CINV) is a major problem for patients treated with high-dose chemotherapy (HDCT) conditioning before stem cell transplantation (SCT), both during chemotherapy and afterwards (delayed nausea/vomiting). The standard of care (5-HT3 antagonist and dexamethasone) appears to be ineffective against delayed nausea and vomiting. The objective of this study was to compare standard antiemetic treatment with standard treatment plus prolonged treatment with aprepitant (Emend®) until 7 days after the end of chemotherapy in patients treated with HDCT before autologous SCT. Ninety-six patients were randomized to the experiment (EXP) group receiving Emend in addition to standard antiemetics or to the control (CTR) group receiving placebo. Emend or placebo treatment started 1 h before the first HDCT dose for SCT and ended 7 days after HDCT. Thirty-eight patients in the EXP group experienced complete response (no vomiting) compared to 16 patients in the CTR group. There was a significant difference between the EXP (0.63 ± 2.71) and the CTR (3.72 ± 4.91) group during 10 days after the end of HDCT (p = 0.001) with regard to the number of vomiting episodes. No difference with regard to days of nausea or in the use of antiemetic rescue was noted between the groups. We conclude that standard antiemetic treatment can be improved by addition of aprepitant continued for 7 days after the end of chemotherapy.

National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-245242 (URN)10.1159/000371523 (DOI)000356945700004 ()25659986 (PubMedID)
Available from: 2015-02-26 Created: 2015-02-26 Last updated: 2017-12-04Bibliographically approved
Svanberg, A., Öhrn, K. & Birgegård, G. (2015). Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation: A pilot study. European Journal of Oncology Nursing, 19, 50-53
Open this publication in new window or tab >>Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation: A pilot study
2015 (English)In: European Journal of Oncology Nursing, ISSN 1462-3889, E-ISSN 1532-2122, Vol. 19, p. 50-53Article in journal (Refereed) Published
Abstract [en]

PURPOSE: To investigate if adding Caphosol(®), a mouthwash solution, to oral cryotherapy (OC) further protects against oral mucositis (OM), a toxic painful complication to high dose chemotherapy.

METHOD: The study was a randomised, controlled, study design. Patients ≥16 years scheduled for allogeneic stem cell transplantation were included consecutively and randomised to experimental group receiving OC combined with Caphosol(®) (n = 20) or control group receiving OC only (n = 20). OC was given from start to end of HDCT. Caphosol(®), from day 0 to day 21.

RESULT: There were no significant differences regarding age or gender between the groups. Mucositis was assessed with the World Health Organisation (WHO) grading scale. Pain was assessed with a 10 cm visual analogue scale (VAS) from 0 = no pain to 10 = worst imaginable pain. Start and duration of therapy with pain relieving drugs, serum C-reactive protein values, and number of days of hospitalisation were collected from the medical records. Data on OM, oral pain, use of i.v. opioids and total parenteral nutrition were collected during 22 days. There was no significant difference between the groups on OM, oral pain, use of i.v. opioids or TPN between the groups.

CONCLUSION: The study showed no additional effect of combining Caphosol(®) with OC.

National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-179503 (URN)10.1016/j.ejon.2014.07.011 (DOI)000350074400009 ()25224595 (PubMedID)
Available from: 2012-08-17 Created: 2012-08-17 Last updated: 2017-12-07Bibliographically approved
Kiani, R., Vasaitis, L., Svanberg, A. & Nordmark, G. (2014). Fatigue correlates with mental health and quality of life in primary Sjogren's syndrome. Scandinavian Journal of Rheumatology, 43(S127), 37-38
Open this publication in new window or tab >>Fatigue correlates with mental health and quality of life in primary Sjogren's syndrome
2014 (English)In: Scandinavian Journal of Rheumatology, ISSN 0300-9742, E-ISSN 1502-7732, Vol. 43, no S127, p. 37-38Article in journal, Meeting abstract (Other academic) Published
National Category
Rheumatology and Autoimmunity
Identifiers
urn:nbn:se:uu:diva-235275 (URN)000341757300056 ()
Available from: 2014-11-03 Created: 2014-10-30 Last updated: 2017-12-05Bibliographically approved
Organisations

Search in DiVA

Show all publications